HOME >> BIOLOGY >> NEWS
Completion of the Drosophila genome sequence

The Drosophila research community thanks Celera Genomics and the publicly-funded genome projects for delivering the fruitfly genome sequence

PITTSBURGH, PENN. March 23, 2000 -- The publication and release of the complete DNA sequence of the fruit fly Drosophila in the current issue of Science reports an achievement that will have enormous impact on understanding human biology and disease. Nearly two-thirds of the genes known to cause human disease are present in the Drosophila genome, including genes responsible for birth defects, neurodegeneration, and cancer. These findings demonstrate that basic research using Drosophila has enormous value in the fight against human disease.

This occasion caps a century of ground-breaking discoveries made using Drosophila, several of which were recognized by Nobel prizes. These include the demonstration that radiation causes mutations and the discovery of genes that control the basic body plan of all organisms.

Drosophila has the largest genome sequence produced to date. This daunting project was only accomplished at an accelerated pace because private industry and government funded public efforts collaborated in a true partnership. The Drosophila Board, representing the community of Drosophila researchers, sincerely thanks Celera Genomics, Inc. and the Drosophila Genome Projects for providing this important resource to our research community.

The completion of the Drosophila genome sequence heralds a new era of biomedical discovery. The Drosophila community welcomes this leap forward and the opportunity it affords to advance our understanding of how organisms function and how genetic defects cause disease.

The Drosophila Genome Project is a consortium of the Berkeley Genome Project, European Genome Project, Baylor College of Medicine Human Genome Center, and FlyBase. The Dros
'"/>

Contact: Gary Karpen
karpen@salk.edu
412-281-3700 ext2606
Salk Institute
22-Mar-2000


Page: 1 2

Related biology news :

1. A room with a view for the International Space Station: Completion of the cupola observation module
2. Completion of comprehensive index of human proteins to be presented at New York Academy Of Sciences
3. Drosophila genome sequence completed
4. Scientists sequence genome of kind of organism central to biospheres carbon cycle
5. Keep genome data freely accessible
6. The book opens on the first tree genome
7. NSF awards 22 new projects for plant genome research
8. Milk genome symposium
9. Environmental decontamination, greenhouse gases, and the genome of a methane-loving bacterium
10. Scientists explore genome of methane-breathing microbe
11. National Academies advisory: genome data and bioterrorism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Completion the genome sequence

(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: